Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
about
Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.Probing protein flexibility reveals a mechanism for selective promiscuity.Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.In-vitro effect of pembrolizumab on different T regulatory cell subsets.Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry.Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD).High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infectionCombination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer
P2860
Q29964482-6AFDD6F1-3B9A-4415-8552-D7A6920B4240Q33732362-008DEFE9-E982-4022-B0ED-BF29DCF47BB9Q33912075-B6FA3E6C-B7DD-4700-A63A-BEBC80847BB0Q37637845-EE78AE3A-70F1-483B-9196-B21CE5DCF938Q38999322-F512EE1B-9570-4535-917E-D73D3D8DE5A6Q39296613-ECA434B8-82B9-4D7A-9D13-67C00E8A510EQ41668880-0F507104-C653-47AC-8E26-527B1AEC3541Q41849636-A05B48DD-D848-46E1-B951-B3C7B013FA73Q47329066-3438DAB4-718E-4306-8917-1D2B407BAE78Q47616276-F8AB1850-8BE7-49CD-A83D-EE445D4A698BQ47783661-522463FC-E2F5-4C78-BA0C-37B2F7EB3FE2Q48043038-31C0558F-49E2-46C2-948A-5F8AD7BE2ED9Q49592680-1DAC544A-979C-4466-B974-3F9B5505AEB1Q49959323-7058BB8B-B15C-410E-A57E-EDE19613ED44Q52630284-895967F7-D6BB-42B6-B232-E0D0F8080F0FQ55243180-DD3E4B3A-0663-4142-89F3-CA0F2F2DD737Q55394825-F771172B-F4DC-4203-A792-D3A68BB520CAQ56888862-6D588BB8-7F9C-487D-8946-6C3F983B13CDQ57201477-1C738252-FCA0-4190-81D7-76790E1BA3B1Q58770914-968AAC5E-FB4A-4358-ABD9-1D427B2DD42C
P2860
Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Structural basis for blocking ...... apeutic antibody pembrolizumab
@ast
Structural basis for blocking ...... apeutic antibody pembrolizumab
@en
Structural basis for blocking ...... apeutic antibody pembrolizumab
@nl
type
label
Structural basis for blocking ...... apeutic antibody pembrolizumab
@ast
Structural basis for blocking ...... apeutic antibody pembrolizumab
@en
Structural basis for blocking ...... apeutic antibody pembrolizumab
@nl
prefLabel
Structural basis for blocking ...... apeutic antibody pembrolizumab
@ast
Structural basis for blocking ...... apeutic antibody pembrolizumab
@en
Structural basis for blocking ...... apeutic antibody pembrolizumab
@nl
P2093
P2860
P3181
P356
P1433
P1476
Structural basis for blocking ...... apeutic antibody pembrolizumab
@en
P2093
Cheng-I Wang
Esra Balıkçı
Haiwei Song
Sakshibeedu R Bharath
Siok Ping Yeo
Zhenkun Na
P2860
P2888
P3181
P356
10.1038/CR.2016.77
P577
2016-06-21T00:00:00Z
P6179
1025242882